Related Experiment Videos
Experimental models of coronary artery restenosis
D W Muller1, S G Ellis, E J Topol
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0022.
Abstract:
The study of potentially effective drug therapies and mechanical devices for the prevention of restenosis after percutaneous coronary revascularization has relied heavily on the use of experimental animal models. To date, greater than 50 experimental studies have been reported and have suggested that at least nine different classes of pharmacologic agents inhibit the intimal proliferative response to arterial injury. However, no pharmacologic intervention has yet been shown to reproducibly reduce the incidence of restenosis after coronary balloon angioplasty in humans. To identify the reasons for the apparent nonspecificity of the animal models and to determine which model should most reliably predict the efficacy of individual therapies in humans, the distinguishing characteristics of the experimental models were compared. Particular attention was paid to the size and morphologic structure of the treated artery, the susceptibility of the species to spontaneous and diet-induced arterial disease, the nature of the stimulus to intimal proliferation and several practical and logistic considerations. Finally, the reported efficacies of specific drug therapies in the respective animal models and in humans were compared. This review suggests that significant interspecies and occasionally intraspecies differences do exist among the respective animal models, particularly in the extent and composition of the neointimal thickening.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Animal models for restenosis research show significant differences in arterial response, impacting the prediction of human treatment efficacy. Further research is needed to refine these models for drug development.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Translational Medicine
Background:
- Percutaneous coronary revascularization (PCR) frequently leads to restenosis.
- Numerous experimental animal models are used to test therapies for restenosis prevention.
- Despite promising preclinical results, few pharmacologic agents have proven effective in humans.
Purpose of the Study:
- To compare the characteristics of experimental animal models used for restenosis research.
- To identify reasons for the poor translation of animal model findings to human clinical outcomes.
- To determine which animal models best predict therapeutic efficacy in humans.
Main Methods:
- Review and comparison of over 50 experimental studies on restenosis animal models.
- Analysis of arterial size, morphology, species susceptibility to arterial disease, and injury stimuli.
- Comparison of drug efficacies reported in animal models versus human clinical trials.
Main Results:
- Significant interspecies and intraspecies differences exist in animal models of restenosis.
- Variations in neointimal thickening extent and composition were observed across models.
- Current animal models show limited reliability in predicting human restenosis treatment outcomes.
Conclusions:
- Existing animal models for restenosis research exhibit considerable variability.
- These differences contribute to the lack of reproducible success in translating therapies to humans.
- Careful selection and characterization of animal models are crucial for effective drug development.